XENETIC BIOSCIENCES, INC. Deferred Tax Assets, Tax Deferred Expense, Other
XENETIC BIOSCIENCES, INC. (XBIO) had Deferred Tax Assets, Tax Deferred Expense, Other of $1.66 million as of 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther · last filed 2026-03-12
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Other $1.66M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Other $1.80M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Other $1.47M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Other $735.70K.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Other |
|---|---|
| 2025-12-31 | $1.66M 10-K · filed 2026-03-12 |
| 2024-12-31 | $1.80M 10-K · filed 2026-03-12 |
| 2023-12-31 | $1.47M 10-K · filed 2025-03-18 |
| 2022-12-31 | $735.70K 10-K · filed 2024-03-21 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-22 |
| 2020-12-31 | $122.89K 10-K · filed 2021-03-16 |
| 2019-12-31 | $142.01K 10-K · filed 2021-03-16 |
| 2018-12-31 | $0.00 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |